NCT07028710 Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle
| NCT ID | NCT07028710 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Luteal Phase Insufficiency |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-01-12 |
| Primary Completion | 2028-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-01-12 with a primary completion date of 2028-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.
Eligibility Criteria
Inclusion Criteria: * At least 1 follicle of 14 mm or more * Endometrium of 6 mm or more * Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng/mL * For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care). Exclusion Criteria: * Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period. * Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion. * Patient who has not given written consent to participate in the study. * Patient not fluent in French. * Patient under guardianship, curators or without social security coverage. * Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .
Contact & Investigator
Noémie RANISAVLJEVIC, Senior Lecturer - Hospital Pra
✉ n-ranisavljevic@chu-montpellier.fr📞 04 67 33 64 81
Noémie RANISAVLJEVIC, Investigator Coordinator
PRINCIPAL INVESTIGATOR
CHU de Montpellier
Frequently Asked Questions
Who can join the NCT07028710 clinical trial?
This trial is open to female participants only, studying Luteal Phase Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07028710 currently recruiting?
Yes, NCT07028710 is actively recruiting participants. Contact the research team at n-ranisavljevic@chu-montpellier.fr for enrollment information.
Where is the NCT07028710 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT07028710 clinical trial?
NCT07028710 is sponsored by University Hospital, Montpellier. The principal investigator is Noémie RANISAVLJEVIC, Investigator Coordinator at CHU de Montpellier. The trial plans to enroll 40 participants.